Ishares Msci Italy ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Ishares Msci Italy ETF trades at $63.12, while State Street SPDR S&P Biotech ETF trades at $159.35. Which is the better fit depends on your goals.
| EWI | XBI | |
|---|---|---|
Sector | Broad Market / Factor | Broad Market / Factor |
52-Week High | $63.35 | $164.28 |
52-Week Low | $50.31 | $86.92 |
Signals from Pluang's Aura AI — not financial advice
EWI trades at $63.18, up 0.02% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock recently hit a 52-week high, driven by positive European market sentiment and Italy's economic recovery narrative. A dividend of $1.17 is scheduled for June 2026, offering income potential.
Outlook is cautiously optimistic given strong technical momentum and favorable European equity flows, but risks include ECB policy shifts and energy price volatility. Investors should weigh technical overbought conditions against fundamental growth prospects in Italy's market.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Trailing returns across standard periods
EWI is a country-specific ETF that tracks the performance of the Italian equity market. It provides targeted access to large and mid-sized companies in Italy, with a heavy focus on the financial sector and holdings like UniCredit and Intesa Sanpaolo.
Read more on EWI →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →